The importance of BCL-2 family proteins in cancer survival spurred the development of a new class of therapeutics called “BH3-mimetics” that can directly inhibit their pro-survival activity, altering the balance of pro- and anti-apoptotic signaling to induce cell death [19] (Supplementary Fig. 1). This evidence concerns the gene BCL2 and cancer.